A Phase I/IIa Multi-center, Open-label, Master Protocol to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Antitumor Activity of AZD8205 in Participants with Advanced or Metastatic Solid Malignancies (D6900C00001)
ENROLLING
Trial ID:
NCT05123482 Protocol # :
23-579
Phase
I/II
Disease Sites
Neuroendocrine/Carcinoid
Gastroesophageal Junction
Gallbladder/Biliary
Other specified personal risk factors, not elsewhere classified
Lip, Oral Cavity and Pharynx
Esophagus
Stomach
Small Intestine
Colon
Rectum
Anus
Liver
Pancreas
Other Digestive Organ
Larynx
Lung
Other Respiratory and Intrathoracic Organs
Bones and Joints
Soft Tissue
Other Skin
Breast
Cervix
Corpus Uteri
Ovary
Other Female Genital
Prostate
Other Male Genital
Urinary Bladder
Kidney
Other Urinary
Eye and Orbit
Brain and Nervous System
Thyroid
Unknown Sites
Ill-Defined Sites
Other Endocrine System
Kaposi's Sarcoma
Melanoma, Skin
Principal Investigator
Liu, Joyce, F
Site Research Nurses
Belavusava, Vera
Doherty, Kelsie
Hindenach, Sarah
McNamara, Taylor
Morrissey, Stephanie, C.
Neals, Allison
Trial Description
Call 877-DF-TRIAL (877-338-7425) to learn more about this clinical trial, protocol #23-579
23-579